The bromoporphyrins as promising anti-tumor photosensitizers in vitro

Photochem Photobiol Sci. 2023 Feb;22(2):427-439. doi: 10.1007/s43630-022-00326-9. Epub 2022 Nov 7.

Abstract

The synthesis of ideal photosensitizers (PSs) is considered to be the most significant bottleneck in photodynamic therapy (PDT). To discover novel PSs with excellent photodynamic anti-tumor activities, a series of novel photosensitizers 5,15-diaryl-10,20-dibromoporphyrins (I1-6) were synthesized by a facile method. Compared with hematoporphyrin monomethyl ether (HMME) as the representative porphyrin-based photosensitizers, it is found that not only the longest absorption wavelength of all compounds was red-shifted to therapeutic window (660 nm) of photodynamic therapy, but also the singlet oxygen quantum yields were significantly increased. Furthermore, all compounds exhibited lower dark toxicity (except I2) and stronger phototoxicity (except I4) against Eca-109 tumor cells than HMME. Among them, I3 possessed the highest singlet oxygen quantum yield (ΦΔ = 0.205), the lower dark toxicity and the strongest phototoxicity (IC50 = 3.5 μM) in vitro. The findings indicated the compounds I3 had the potential to become anti-tumor agents for PDT.

Keywords: Anti-tumor; Bromoporphyrin; Photodynamic therapy; Photosensitizer.

MeSH terms

  • Humans
  • Neoplasms* / drug therapy
  • Photochemotherapy*
  • Photosensitizing Agents / chemistry
  • Porphyrins* / chemistry
  • Singlet Oxygen / chemistry

Substances

  • Photosensitizing Agents
  • Singlet Oxygen
  • Porphyrins